{"protocolSection": {"identificationModule": {"nctId": "NCT02150499", "orgStudyIdInfo": {"id": "SEP051-361"}, "organization": {"fullName": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects", "officialTitle": "A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to \u2264 48 Months of Age With Reactive Airways Disease in an Acute Setting"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-05-27", "studyFirstSubmitQcDate": "2014-05-27", "studyFirstPostDateStruct": {"date": "2014-05-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-18", "resultsFirstSubmitQcDate": "2016-01-04", "resultsFirstPostDateStruct": {"date": "2016-02-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-10", "lastUpdatePostDateStruct": {"date": "2016-04-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to \u2264 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.", "detailedDescription": "This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to \u2264 48 months of age with acute bronchospasm. It is a randomized, double-blind, parallel-group, multicenter, trial of 3 doses of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to \u2264 48 months of age who present to either the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.\n\nEligible subjects whose parent(s) or legal guardian(s) provide written informed consent to participate will be randomized to 1 of 2 treatments. Treatment 1 consists of 3 doses, with each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA \\[cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\\]); Treatment 2 consists of 3 doses, with each dose comprised of 8 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff \\[cumulative dose of 1080 mcg of levalbuterol tartrate HFA inhalation aerosol\\]). For each Treatment, study medication will be administered every 20 minutes over a period of 1 hour for three doses."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Acute Asthma exacerbation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "levalbuterol tartrate HFA inhalation aerosol plus placebo HFA", "type": "EXPERIMENTAL", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol", "interventionNames": ["Drug: levalbuterol tartrate HFA inhalation aerosol", "Drug: placebo"]}, {"label": "levalbuterol tartrate HFA inhalation aerosol plus levalbuterol", "type": "EXPERIMENTAL", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.", "interventionNames": ["Drug: levalbuterol tartrate HFA inhalation aerosol"]}], "interventions": [{"type": "DRUG", "name": "levalbuterol tartrate HFA inhalation aerosol", "armGroupLabels": ["levalbuterol tartrate HFA inhalation aerosol plus levalbuterol", "levalbuterol tartrate HFA inhalation aerosol plus placebo HFA"], "otherNames": ["Xopenex HFA\u00ae (Levalbuterol tartrate) Inhalation Aerosol"]}, {"type": "DRUG", "name": "placebo", "armGroupLabels": ["levalbuterol tartrate HFA inhalation aerosol plus placebo HFA"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Week 1"}, {"measure": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Week 1"}, {"measure": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Week 1"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Pulmonary Score (Total Score) to End of Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Day 1"}, {"measure": "Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Day 1"}, {"measure": "Change From Baseline in Pulmonary Score (Total Score) After Each Dose", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "20 minutes, 40 minutes, 60 minutes"}, {"measure": "Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "20 minutes, 40 minutes, 60 minutes"}, {"measure": "Number and Percentage of Subjects Determined to be Stabilized After Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "timeFrame": "Day 1"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female from birth to 48 months of age, inclusive, whose parent(s) or legal guardian(s) provide written informed consent prior to study participation and are willing to comply with study procedures.\n2. Subject experiencing acute bronchospasm requiring a bronchodilator and who have a history of wheezing.\n\nExclusion Criteria:\n\n1. Subject with a severe illness that, in the opinion of the Investigator, could jeopardize subject safety.\n2. Subject received \u2265 8 puffs (MDI) of a beta-2 agonist or 2.5 mg of nebulized levalbuterol, or albuterol 5.0 mg within 4 hours prior to ED or physician's office admittance.\n3. Subject received ipratropium within 4 hours prior to ED or physician's office admittance.\n4. Subject who participated in an investigational drug study within 30 days prior to enrollment, or who previously participated in the current study.\n5. Subject with a known sensitivity to levalbuterol or racemic albuterol or any of the excipients contained in any of these formulations.\n6. Subject using any prescription drug (including beta-blockers) with which levalbuterol or racemic albuterol sulfate administration is contraindicated.\n7. Subject with a history of clinically significant abnormalities that could interfere with the metabolism or excretion of the study medication (eg, renal, hepatic, metabolic, or endocrine abnormalities).\n8. Subject with a history of cancer.", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "48 Months", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Respiratory Medical Director, MD", "affiliation": "Sumitomo Pharma America, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Score Physician Alliance, LLC", "city": "Saint Petersburg", "state": "Florida", "zip": "33710", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Northern Illinios Research Associates", "city": "Dekalb", "state": "Illinois", "zip": "60115", "country": "United States", "geoPoint": {"lat": 41.92947, "lon": -88.75036}}, {"facility": "Northern Illinois Associates", "city": "Dekalb", "state": "Illinois", "zip": "60115", "country": "United States", "geoPoint": {"lat": 41.92947, "lon": -88.75036}}, {"facility": "Michael W. Simon, MD, PSC", "city": "Nicholasville", "state": "Kentucky", "zip": "40356", "country": "United States", "geoPoint": {"lat": 37.88063, "lon": -84.573}}, {"facility": "Willis-Knighton Physician Network / Portico Pediatrics", "city": "Shreveport", "state": "Louisiana", "zip": "71105", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "Mid Michigan Sleep Center", "city": "Grand Blanc", "state": "Michigan", "zip": "48439", "country": "United States", "geoPoint": {"lat": 42.92753, "lon": -83.62995}}, {"facility": "Craig Spiegel, MD", "city": "Bridgeton", "state": "Missouri", "zip": "63044", "country": "United States", "geoPoint": {"lat": 38.767, "lon": -90.41151}}, {"facility": "St. Peter's University Hospital", "city": "New Brunswick", "state": "New Jersey", "zip": "08901", "country": "United States", "geoPoint": {"lat": 40.48622, "lon": -74.45182}}, {"facility": "Capital Pediatrics & Adolescent Center PLLC", "city": "Raleigh", "state": "North Carolina", "zip": "27609", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Capitol Pediatric & Adolescent Center PLLC", "city": "Raleigh", "state": "North Carolina", "zip": "27609", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Dayton Clinical Research", "city": "Dayton", "state": "Ohio", "zip": "45406", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Charleston Allergy & Asthma Research", "city": "Summerville", "state": "South Carolina", "zip": "29485", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "TTS Research", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Allergy Asthma Research Institute", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "PI-Coor Clinical Research", "city": "Burke", "state": "Virginia", "zip": "22015", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "Advanced Pediatrics", "city": "Vienna", "state": "Virginia", "zip": "22180", "country": "United States", "geoPoint": {"lat": 38.90122, "lon": -77.26526}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "FG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Pediatric subjects birth to less than or equal to 48 months of age with reactive airways disease in an acute setting", "groups": [{"id": "BG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "BG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18.6", "spread": "10.21"}, {"groupId": "BG001", "value": "17.1", "spread": "12.75"}, {"groupId": "BG002", "value": "17.8", "spread": "11.23"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Adverse Events", "timeFrame": "Week 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "PRIMARY", "title": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Serious Adverse Events", "timeFrame": "Week 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation.", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Discontinuations", "timeFrame": "Week 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Score (Total Score) to End of Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Score (Total Score) After Each Dose", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "timeFrame": "20 minutes, 40 minutes, 60 minutes", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "timeFrame": "20 minutes, 40 minutes, 60 minutes", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Number and Percentage of Subjects Determined to be Stabilized After Treatment", "description": "Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.", "reportingStatus": "POSTED", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo"}, {"id": "OG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "three months", "eventGroups": [{"id": "EG000", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\n\nlevalbuterol tartrate HFA inhalation aerosol\n\nplacebo", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 2, "otherNumAtRisk": 9}, {"id": "EG001", "title": "Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol", "description": "Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.\n\nlevalbuterol tartrate HFA inhalation aerosol", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 2, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Bronchial hyperreactivity", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Existaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Stridor", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Termor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish"}, "pointOfContact": {"title": "Respiratory Medical Director", "organization": "Sunovion Pharmaceuticals Inc.", "email": "clinicaltrialsdisclousre@sunovion.com", "phone": "1-866-503-6351"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000053120", "term": "Respiratory Aspiration"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012120", "term": "Respiration Disorders"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "asFound": "Inhalation", "relevance": "HIGH"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M14957", "name": "Respiration Disorders", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Belarus", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}